Drugs / ONT-10
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02270372 | Nov 2014 → Jun 2016 | breast carcinoma, ovarian carcinoma | Cascadian Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01556789 | Mar 2013 → May 2015 | cancer | Cascadian Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01978964 | Nov 2012 → Mar 2016 | cancer | Cascadian Therapeutics Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ONT-10 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01978964 ↗ |
| Modality | Vaccine | “a Liposomal MUC1 Cancer Vaccine” NCT01556789 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT01556789 ↗ |
| Target | MUC1 | “ONT-10 a liposomal synthetic glycopolypeptide MUC1 targeted antigen formulated with PET Lipid A adjuvant.” NCT02270372 ↗ |